Phaseline

Companies › Shenzhen Salubris Pharmaceuticals

Shenzhen Salubris Pharmaceuticals: clinical trials, targets and expected readouts

8 active drug programs in 25 registered trials: 13 Phase 2, 6 Phase 1, 4 Phase 4, 2 Phase 3; Cardiovascular, Metabolic and endocrine, Other, Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Losartan
Type-1 angiotensin II receptor antagonist
AGTR1Phase 4Healthy Participants; Atrial Fibrillation; Diabetes Mellitus, Type 2; Heart Valve Diseases …–
SAL056
GLP-1 receptor agonist
–Phase 2Postmenopausal Women With OsteoporosisNov 2026
SAL0140–Phase 2Uncontrolled HypertensionMar 2027
GW906–Phase 2Hypertension–
SAL-0951
Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor
–Phase 2Anemia–
SAL0120–Phase 2Chronic Kidney Disease–
SAL0133–Phase 1Pharmacokinetics–
SAL0137
Lipoprotein(a) [Lp(a)] reduction mechanism unclear
–Phase 1Healthy Participants–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07030504SAL0133Phase 1PharmacokineticsOtherJun 2025
NCT05619653LosartanPhase 3COVID-19 Associated Cardiac InvolvementCardiovascularAug 2025
NCT07174830LosartanPhase 4Healthy ParticipantsOtherDec 2025
NCT06737081SAL-0951Phase 2AnemiaHematologyDec 2025
NCT07051603SAL0140Phase 1Uncontrolled HypertensionCardiovascularJan 2026
NCT07716618SAL0120Phase 2Chronic Kidney DiseaseGenitourinaryMay 2026
NCT07586371LosartanPhase 2ProteinuriaMetabolic and endocrineJul 2026
NCT07835971GW906Phase 2HypertensionCardiovascularSep 2026
NCT07745114SAL0137Phase 1Healthy ParticipantsMetabolic and endocrineSep 2026
NCT07579936SAL056Phase 2Postmenopausal Women With OsteoporosisMetabolic and endocrineNov 2026
NCT01199978LosartanPhase 2Vestibular SchwannomaOncologyDec 2026
NCT06211335LosartanPhase 1Locally Recurrent Head and Neck Squamous Cell CarcinomaOncologyDec 2026
NCT04111419LosartanPhase 4Atrial FibrillationCardiovascularDec 2026
NCT05077800LosartanPhase 2Pancreatic AdenocarcinomaOncologyDec 2026
NCT07654140SAL0140Phase 2Uncontrolled HypertensionCardiovascularMar 2027
NCT02560805LosartanPhase 2Stress Disorders, Post-TraumaticPsychiatryMar 2027
NCT03563248LosartanPhase 2Pancreatic CancerOncologyApr 2027
NCT06364176LosartanPhase 2Cystic FibrosisRespiratoryMay 2027
NCT03900793LosartanPhase 1OsteosarcomaOncologyAug 2027
NCT05637216LosartanPhase 2Radiation Induced FibrosisOncologyAug 2027
NCT06143566LosartanPhase 1Type 2 DiabetesMetabolic and endocrineSep 2027
NCT05331144LosartanPhase 2Cognitively Normal Older AdultsNeurologyJun 2028
NCT03264352LosartanPhase 4Diabetes Mellitus, Type 2CardiovascularSep 2028
NCT07569640LosartanPhase 3Heart Failure With Reduced Ejection FractionCardiovascularApr 2029
NCT07099859LosartanPhase 4Heart Valve DiseasesCardiovascularJul 2029

Targets

AGTR1 (1)

Companies with the same targets

THPharm HB BioTech Chong Kun Dang Pharmaceutical Yuhan Travere Therapeutics Shin Poong Pharmaceutical Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Shin Poong Pharmaceutical JW Pharmaceutical Suzhou Alphamab Shanghai Minwei Biotechnology Fujian Shengdi Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.